EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

High fear of cancer recurrence (FCR) impacts patient's quality of life (QoL) and is prevalent among patients with familial melanoma. The main objective is to investigate whether EMDR is effective in treating high FCR in patients with familial melanoma. The study design is a non-blinded, randomized waiting-list controlled trial. Patients aged 18 years or older with familial melanoma can be included. Patients with high FCR will receive a maximum of 4, 90 minutes, EMDR-sessions. The main study parameter is the decrease and level of FCR measured with the Cancer Worry Scale (CWS). The secondary study parameter is quality of life, measured with the EORTC.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• a score of 16 or higher on the FCRI-NL-SF

• 18 years or older

• diagnosed with familial melanoma

Locations
Other Locations
Netherlands
Leiden University Medical Center
RECRUITING
Leiden
Leiden University Medical Centre
RECRUITING
Leiden
Contact Information
Primary
Sanne K. de Bie, Drs.
s.k.de_bie@lumc.nl
0031 71 526 3615
Backup
Chris Hinnen, Dr.
s.c.h.hinnen@lumc.nl
0031 71 526 3615
Time Frame
Start Date: 2023-11-01
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 30
Treatments
Experimental: Intervention
Those assigned to the intervention condition will start EMDR treatment immediately after enrolment. The intervention will consist of an intake (90 min) and a maximum of 4 EMDR sessions (90 min each). After inclusion, baseline characteristic (sociodemographic and clinical variables) will be assessed. Moreover, before start EMDR treatment, after the last EMDR session and 2 weeks- and 3 months after ending EMDR treatment FCR and quality of life will be assessed.
No_intervention: Waiting-list
Those assigned to the waiting-list will wait for 6 weeks. After these 6 weeks those assigned to the waiting list condition are able to receive the same treatment and the same assessment schedule when FCR is still present.
Sponsors
Leads: Leiden University Medical Center
Collaborators: Erasmus Medical Center

This content was sourced from clinicaltrials.gov